

## 9 Literatura

- Afshan S, Farah Musa AR, Echols V, Lerant AA, Fülöp T (2017). Persisting Hypocalcemia After Surgical Parathyroidectomy: The Differential Effectiveness of Calcium Citrate Versus Calcium Carbonate With Acid Suppression. *Am J Med Sci.* 353(1): 82–86.
- Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd. (2014). Trends in fracture incidence: a population-based study over 20 years. *J Bone Miner Res.* 29(3): 581–589.
- Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O et al. (2014). Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. *J Bone Miner Res.* 29: 518–530.
- Bartl R. Osteopatie indukovaná antiepileptiky – formy, patogeneze, prevence, časná diagnóza a léčba. *Medicína po promoci* 5/2007.
- Bastías JM, Balladares P, Acuña S, Quevedo R, Muñoz O (2017). Determining the effect of different cooking methods on the nutritional composition of salmon (*Salmo salar*) and chilean jack mackerel (*Trachurus murphyi*) fillets. *PLoS One.* 2017 Jul 7; 12(7): e0180993. doi: 10.1371/journal.pone.0180993. eCollection 2017.
- Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S et al. FLEX Research Group (2006). Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA.* 296(24): 2927–2938.
- Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN et al. (2012). Postmenopausal Osteoporosis Treatment With Antiresorptives: Effects of Discontinuation or Long-Term Continuation on Bone Turnover and Fracture Risk-A Perspective. *JBMR*, 27, p. 963–974.
- Brešnajdrová M, Terrichová M, Závodný P (2011). Kalcium a vitamin D u seniorů. *Med. praxi* 2011; 8(4): 163–166.
- Broulík P (2008). Dvojitý účinek parathormonu na kostní tkáň. *Interní Med.* 10(5): 224–226.
- Broulík P (2009). Osteoporóza a její léčba. Praha: Maxdorf.
- Broulík P (2016). Význam suplementace kalcia a vitaminu D v léčbě osteoporózy. *Remedia* 26(1): 62–66.
- Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S et al. (2017). Skeletal health in breast cancer survivors. *Maturitas.* 105: 78–82.

- Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA (2017). Estrogens in male physiology. *Physiol Rev* 97: 995–1043.
- Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC et al. (2011). Secular trends in the incidence of hip and other osteoporotic fractures. *Osteoporos Int.* 22(5): 1277–1288.
- Cooper C, Fox KM, Borer JS (2014). Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. *Osteoporos Int.* 25(2): 737–745.
- Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V et al. (2008). The effects of tibolone in older postmenopausal women. *N Engl J Med*; 359: 697–708.
- Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R et al. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*; 361: 756–765.
- Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S et al. (2007). Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. *Osteoporos Int.*; 18(9): 1211–1218.
- Ebeling PR (2009). Approach to the patient with transplantation-related bone loss. *J Clin Endocrinol Metab.* 94(5): 1483–1490.
- Epstein S, Zaidi M (2005). Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. *Bone.* 37(4): 433–440.
- Fojtík P, Urban O, Falt P, Novosad P (2009). Výživa a sekundární osteoporóza. *Interní Med.* 11(12): 561–568.
- Gajic-Veljanoski O, Papaioannou A, Kennedy C, Ioannidis G, Berger C et al. (2018). Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study. *BMC Geriatr.* 18(1): 4. doi: 10.1186/s12877-017-0692-0.
- Gedmintas L, Solomon DH, Kim SC (2013). Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. *J Bone Miner Res.* 28(8): 1729–1737.
- Gennari L, Bilezikian JP (2018). New and developing pharmacotherapy for osteoporosis in men. *Expert Opin Pharmacother.* 19(3): 253–264.
- Gennari L, Khosla S, Bilezikian JP (2008). Estrogen and fracture risk in men. *J Bone Miner Res.* 23(10): 1548–1551.
- Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA et al. (2010). Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. *J Bone Miner Res.* 25(3): 463–471.
- Horák P (2012). Struktura kosti, léčba osteoporózy a hojení zlomenin. *Interní Med.* 14(11): 441–442.

- Horák P, Skácelová M, Žurek M, Smržová A, Ciferská H (2011). Nové léky u postmenopauzální osteoporózy. *Med. praxi*, 8(3): 104–110.
- Hrdý P, Novosad P (2011). Léčba osteoporózy – současné možnosti *Med. praxi*, 8(12): 523–527.
- Jelínek R et al. Histologie embryologie [online]. 3. lékařská fakulta UK. s. 75–77. Dostupné online. Dne 17. 2. 2018.
- Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD et al. (2014). A meta-analysis of the association of fracture risk and body mass index in women. *J Bone Miner Res.* 29(1): 223–233.
- Kasper H (2015). *Výživa v medicíně a dietetika: Překlad 11. vydání.* Praha: Grada, s. 65.
- Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016). Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. *Osteoporos Int.* 27(3): 853–859.
- Khosla S, Hofbauer LC (2017). Osteoporosis treatment: recent developments and ongoing challenges. *Lancet Diabetes Endocrinol.* 5(11): 898–907.
- Liu Y, Cao Y, Zhang S, Zhang W, Zhang B et al. (2018). Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. *Climacteric.* 9: 1–7.
- Lu Z, Chen TC, Zhang A, Persons KS, Kohn N et al. (2007). An Evaluation of the Vitamin D<sub>3</sub> Content in Fish: Is the Vitamin D Content Adequate to Satisfy the Dietary Requirement for Vitamin D? *J Steroid Biochem Mol Biol.* 103(3–5): 642–644.
- Marek J et al. (2010). *Farmakoterapie vnitřních nemocí.* Praha: Grada, s. 417–425.
- Marshall WJ, Lapsley M, Day A, Ayling R (2014). *Clinical Biochemistry: Metabolic and Clinical Aspects.* 3 rd ed. Churchill Livingstone, Londýn, s. 614–621.
- Micozkadioglu H, Ozelsancak R, Yildiz I, Erken E, Zumrutdal A et al. (2013). Circadian rhythm of serum phosphate, calcium and parathyroid hormone levels in hemodialysis patients. *Clin Lab.* 59(1–2): 79–84.
- Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E et al. (2016). Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. *JAMA.* 16; 316(7): 722–733.
- Murray RK, Granner DK, Mayes PA, Rodwell VW (2002). *Harperova biochemie.* Praha: H & H, s. 544–547.
- Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA et al. (2001). Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med.* 344(19): 1434–1441.
- Ni Y, Fan D (2017). Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies *Medicine (Baltimore).* 96(51): e8811. doi: 10.1097/MD.00000000000008811.
- Pack AM (2003). The Association Between Antiepileptic Drugs and Bone Disease. *Epilepsy Curr.* 3(3): 91–95.

- Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D et al. (2017). Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. *J Clin Endocrinol Metab.* 102(10): 3621–3634.
- Ralston SH. Paget disease of bone. In: Goldman L, Schafer AI, eds. *Goldman's Cecil Medicine*. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016: chap 247.
- Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L (2017). Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. *Semin Arthritis Rheum.* 2017 Dec 7. pii: S0049-0172(17)30649-2. doi: 10.1016/j.semarthrit.2017.12.001.
- Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R et al. (2008). Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. *Arthritis Rheum;* 58(6): 1687–1695.
- Riggs BL, Hartmann LC (2003). Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice *N Engl J Med.* 348(7): 618–629.
- Rosa J (2016). Osteoporóza u mužů. *Osteologický bulletin.* 21(2): 42–48.
- Rosina J, Kolářová H, Stanek J (2006). *Biofyzika pro studenty zdravotnických oborů.* Praha: Grada, s. 170.
- Růžicková O (2017). Možnosti léčby osteoporózy. *Interní Med.* 19(5): 237–345.
- Saag KG, Shane E, Boonen S, Marín F, Donley DW et al. (2007). Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med.* 357(20): 2028–2039.
- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M et al. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med.* 377: 1417–1427.
- Scheinost M, Pavelka K, Skácelová S, Šimková G, Svobodová R (2006). Prevence a terapie glukokortikoidy indukované osteoporózy. *Interní Med.* 9: 389–392.
- Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE et al. (2010). Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. *J Bone Miner Res.* 25(5): 976–982.
- Skácelová S (2011). Denosumab. *Remedia* 21: 230–237.
- Souček M et al. (2011). *Vnitřní lékařství.* Praha: Grada, s. 844–845.
- van Staa TP (2006). The patogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. *Calcif Tissue Int.* 79(3): 129–137.
- Sutter SA, Stein EM (2016). The Skeletal Effects of Inhaled Glucocorticoids *Curr Osteoporos Rep.* 14(3): 106–113.
- Stepan JJ, Vaculik J, Pavelka K, Zofka J, Johansson H et al. (2012). Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. *Calcif Tissue Int.* 90(5): 365–372.
- Štěpán J (2018). Osteoporóza, chronický zánět, mikrobiom a estrogeny. *Remedia* 28(1): 28–34.

- Štěpánková J, Dusilová-Sulková S (2010). Novinky v diagnostice a léčbě renální kostní choroby. *Interní Med.* 12(2): 67–71.
- Tennis P, Rothman KJ, Bohn RL et al. (2012). Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. *Pharmacoepidemiol Drug Saf.* 21(8): 810–817.
- Törring O (2015). Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. *Ther Adv Musculoskelet Dis.* 7(3): 88–102.
- Yang S, Lix LM, Yan L, Hinds AM, Leslie WD (2017). International Classification of Diseases (ICD)-coded obesity predicts risk of incident osteoporotic fracture. *PLoS One.* 12(12): e0189168. doi: 10.1371/journal.pone.0189168. eCollection 2017.
- Vyskočil V (2006). Antiresorpční léčiva v terapii osteoporózy a v redukci relativního rizika zlomenin. *Remedia* 16(4): 332–338.
- Vytrisalova M, Touskova T, Ladova K, Fuksa L, Palicka V et al. (2015). Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. *Climacteric.* 18(4): 608–616.
- Wang H, Bua P, Capodice J (2014). A comparative study of calcium absorption following a single serving administration of calcium carbonate powder versus calcium citrate tablets in healthy premenopausal women. *Food Nutr Res.* 58. doi: 10.3402/fnr.v58.23229. eCollection 2014.
- [www.iofbonehealth.org](http://www.iofbonehealth.org), online dne 16. 2. 2018.
- [www.nof.cz](http://www.nof.cz), online dne 23. 3. 2018.
- [www.nutridatabaze.cz](http://www.nutridatabaze.cz), Ústav zemědělské ekonomiky a informací, online dne 17. 2. 2018.
- [www.smos.cz](http://www.smos.cz), online dne 15. 2. 2018.